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Patients with chemorefractory mantle cell lymphoma (MCL) have a poor prognosis. We used the Center for
International Blood and Marrow Transplant Research database to study the outcome of 202 patients with
refractory MCL who underwent allogeneic hematopoietic cell transplantation (allo-HCT) using either mye-
loablative (MA) or reduced-intensity/nonmyeloablative conditioning (RIC/NST), during 1998-2010. We
analyzed nonrelapse mortality (NRM), progression/relapse, progression-free survival (PFS), and overall
survival (OS). Seventy-four patients (median age, 54 years) received MA, and 128 patients (median age, 59
years) received RIC/NST. Median follow-up after allo-HCT was 35 months in the MA group and 43 months in
the RIC/NST group. At 3 years post-transplantation, no signiﬁcant between-group differences were seen in
terms of NRM (47% in MA versus 43% in RIC/NST; P ¼ .68), relapse/progression (33% versus 32%; P ¼ .89), PFS
(20% versus 25%; P ¼ .53), or OS (25% versus 30%; P ¼ .45). Multivariate analysis also revealed no signiﬁcant
between-group differences in NRM, relapse, PFS, or OS; however, receipt of a bone marrow or T celledepleted
allograft was associated with an increased risk of NRM and inferior PFS and OS. Our data suggest that despite
a refractory disease state, approximately 25% of patients with MCL can attain durable remission after allo-
HCT, and conditioning regimen intensity does not inﬂuence outcome of allo-HCT.
 2013 American Society for Blood and Marrow Transplantation.INTRODUCTION immunochemotherapy either alone [2] or as induction
Mantle cell lymphoma (MCL) accounts for approximately
6% of non-Hodgkin lymphomas (NHL) and typically presents
as advanced-stage disease that frequently involves bone
marrow, peripheral blood, and extranodal sites [1]. MCL
generally follows an aggressive clinical course, with
frequent relapses after conventional chemotherapy regimens.
Over the last decade, strategies including multiagentdgments on page 630.
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13.01.009therapy, followed by consolidation with high-dose therapy
andautologoushematopoietic cell transplantation (auto-HCT)
[3-5] or rituximab maintenance [6,7], have produced higher
response rates and improved disease-free survival. Although
thesemodalities have undoubtedly improved the prognosis of
patients with MCL [8], the disease course remains character-
ized by frequent relapses. After ﬁrst relapse, the prognosis of
MCL ispoor,withamedian survival of approximately1-2years
[9]. This is especially true for patients with relapsedMCLwith
chemotherapy-refractory disease.
The results of auto-HCT in patients with chemorefractory
MCL have been uniformly disappointing [10-12]. Allogeneic
hematopoietic cell transplantation (allo-HCT) is a potentiallyTransplantation.
M. Hamadani et al. / Biol Blood Marrow Transplant 19 (2013) 625e631626curative modality for a variety of hematologic malignancies,
including indolent and aggressive lymphomas [13-17].
Advantages of allo-HCT include a tumor-free graft, as well as
a potential allogeneic effect exerted by donor T cells, known
as the graft-versus-lymphoma effect.
Despite the greater risk of transplantation-related
morbidity and mortality with allo-HCT, selected patients
with relapsed MCL, especially those with chemosensitive
disease, can achieve long-term remission after allo-HCT [18-
20]. Patients with MCL who are refractory to salvage
chemotherapy have a very poor prognosis, however, and
only limited data are available on outcomes after allo-HCT in
this extremely high-risk group. However, because the graft-
versus-lymphoma effect can occur even in the absence of
chemosensitivity, in theory allo-HCT may still offer beneﬁts
even in chemoresistant patients. Moreover, the inﬂuence of
conditioning regimen intensitydthat is, myeloablative (MA)
conditioning versus reduced-intensity conditioning (RIC) or
nonmyeloablative conditioning (NST) regimensdin this
uniquely chemorefractory cohort of patients is not known.
Here we report outcomes of allo-HCT in patients with
refractory MCL relative to the intensity of pretransplantation
conditioning regimens using the observational database of
the Center for International Blood and Marrow Transplant
Research (CIBMTR). This report represents the largest study
of patients with chemotherapy-unresponsive MCL under-
going allo-HCT to date.PATIENTS AND METHODS
Data Sources
The CIBMTR is a research afﬁliation of the International Bone Marrow
Transplant Registry (IBMTR) and the National Marrow Donor Program
(NMDP) established in 2004. Both the IBMTR and the NMDP had been col-
lecting data for more than 1 decade before the establishment of the CIBMTR.
The CIBMTR is a voluntary working group of more than 450 transplantation
centers worldwide that contribute detailed data on consecutive auto-HCTs
and allo-HCTs to a Statistical Center at the Medical College of Wisconsin,
Milwaukee, Wisconsin and the NMDP Coordinating Center in Minneapolis,
Minnesota.
Participating transplantation centers are required to report all HCTs
consecutively, with compliance monitored by onsite audits. Patients are
followed longitudinally, with yearly follow-up. Computerized checks for
discrepancies, physicians’ reviews of submitted data, and onsite audits of
participating centers ensure data quality. Observational studies conducted
by the CIBMTR are performed in compliance with HIPAA regulations as
a public health authority and in compliance with all applicable federal
regulations pertaining to the protection of human research participants, as
determined by continuous review of the Institutional Review Boards of the
NMDP and the Medical College of Wisconsin since 1985.
The CIBMTR collects data at 2 levels: transplant essential data (TED) and
comprehensive report form (CRF) data. TED data include disease type, age,
sex, pretransplantation disease stage and chemotherapy-responsiveness,
date of diagnosis, graft type (bone marrowe and/or blood-derived
progenitor cells), conditioning regimen, post-transplantation disease
progression and survival, development of a new malignancy, and cause of
death. All CIBMTR teams contribute TED data. More detailed disease and
pretransplantation and post-transplantation clinical information are
collected from a subset of registered patients selected for CRF data by
a weighted randomization scheme. TED and CRF level data are collected
pretransplantation, at 100 days post-transplantation, at 6 months post-
transplantation, and annually thereafter up to death.Patients
The study population included all patients with chemotherapy-
unresponsive MCL who underwent allo-HCT reported to the CIBMTR
between 1998 and 2010. Patients with evidence of chemosensitive disease
(ie, those in complete remission or partial remission [PR]) at the time of allo-
HCT were excluded. Pediatric patients (n ¼ 5) and recipients of planned
tandem auto/allo-HCT (n ¼ 50), syngeneic HCT (n ¼ 7), and umbilical cord
blood transplantation (n ¼ 29) were not included in the analysis. The
patient- and disease-related variables that are not reported for registration-
only patients are indicated in Table 1.Deﬁnitions
Conditioning regimens were categorized based on intensity as either
MA or RIC/NST using established consensus criteria [21]. Previously estab-
lished criteria for categorizing the degree of HLA matching were used for
unrelated donor transplants [22]. Well-matched patients had either no
identiﬁed HLAmismatching and informative data at 4 loci or allele matching
at HLA-A, -B, and -DRB1 (6/6). Partially matched pairs had a deﬁned, single-
locus mismatch and/or missing HLA data. Mismatched cases had 2 or more
allele or antigen mismatches.
Study Endpoints
Primary outcomes were nonrelapse mortality (NRM), progression/
relapse, progression-free survival (PFS), and overall survival (OS). NRM was
deﬁned as death from any cause during the ﬁrst 28 days after trans-
plantation or death without evidence of lymphoma progression/relapse;
relapsewas considered a competing risk. Progression/relapsewas deﬁned as
progressive lymphoma after HCT or lymphoma recurrence after a complete
remission; NRM was considered a competing risk. For PFS, a patient was
considered a treatment failure at the time of progression/relapse or death
from any cause. For relapse, NRM, and PFS, patients alive without evidence
of disease relapse or progression were censored at last follow-up. OS was
deﬁned as the interval from the date of transplantation to the date of death
or last follow-up.
Other outcomes analyzed included acute and chronic graft-versus-host
disease (GVHD) and cause of death. Acute GVHD was deﬁned and graded
based on the pattern and severity of organ involvement using established
criteria [23]. Chronic GVHDwas deﬁned as the development of any evidence
of chronic GVHD based on clinical criteria [24]. Neutrophil engraftment was
deﬁned as the ﬁrst of 3 successive days with an absolute neutrophil count
0.5  109/L after a post-transplantation nadir. Platelet engraftment was
considered to have occurred on the ﬁrst of 3 consecutive days with a platelet
count 20  109/L, in the absence of platelet transfusion for 7 consecutive
days. For engraftment and GVHD, death without the event was considered
a competing risk.
Statistical Analysis
Probabilities of PFS and OS were calculated using the Kaplan-Meier
estimator, with variance estimated using the Greenwood formula. Proba-
bilities of NRM, lymphoma progression/relapse, acute and chronic GVHD,
and engraftment were calculated using cumulative incidence curves to
accommodate for competing risks [25]. Patient-, disease-, and
transplantation-related factors were compared between the RIC/NST and
MA groups using the c2 test for categorical variables and the Wilcoxon 2-
sample test for continuous variables. Associations among patient-,
disease-, and transplantation-related variables and outcomes of interest
were evaluated using multivariate Cox proportional hazards regression. A
stepwise selection multivariate model was built to identify covariates that
inﬂuenced outcomes. Covariates with a P value <.05 were considered
signiﬁcant. The proportionality assumption for Cox regressionwas tested by
adding a time-dependent covariate for each risk factor and each outcome.
Covariates violating the proportional hazards assumption were stratiﬁed in
the Cox regression model. Results are expressed as relative risk (RR) or the
relative rate of occurrence of the event.
The following variables were reported for both registration-level and
research-level patients and were considered in multivariate analyses: age at
allo-HCT, sex, Karnofsky Performance Score (KPS) at allo-HCT, previous
auto-HCT, time interval between diagnosis and allo-HCT, disease status at
allo-HCT, conditioning regimen intensity (RIC/NST versus MA), donor type,
donorerecipient sex match, graft source, year of allo-HCT, and type of GVHD
prophylaxis.
RESULTS
Patient-, Disease-, and Transplantation-Related
Variables
Between 1998 and 2010, a total of 202 patients under-
went allo-HCT for refractory MCL, 74 with MA allo-HCT and
128 with RIC/NST allo-HCT. Median follow-up of survivors
was 35 months in the MA group and 43 months in the RIC/
NSTgroup. The follow-up completion rate at 3 years was 80%
in both groups, reﬂecting good follow-up to that time point
[26]. Table 1 presents patient-, disease-, and transplantation-
related characteristics of the 2 groups. The RIC/NST group
was older than theMA group (median age, 59 years versus 54
years; P < .001). Approximately half of the patients in both
groups had a pretransplantation KPS <90. Median time from
Table 1
Characteristics of Patients with Refractory MCL who Underwent Allo-HCT Reported to the CIBMTR between 1998 and 2010
Variable MA RIC/NST P Value
Patient-related
Number of patients 74 128
Number of centers 28 63
Age, years, median (range) 54 (27-69) 59 (42-75) <.001
Male sex, n (%) 63 (85) 99 (77) .181
KPS <90%, n (%) 36 (49) 61 (48) .264
Disease related
Disease stage at diagnosis, n (%)* .836
I-II 2 (11) 5 (8)
III-IV 14 (78) 52 (84)
Missing 2 (11) 5 (8)
Extranodal involvement before allo-HCT, n (%)* .616
No 2 (11) 11 (18)
Yes 14 (78) 51 (82)
Missing 2 (11) 0
Central nervous system involvement before allo-HCT, n (%)* .467
No 16 (89) 60 (97)
Yes 0 2 (3)
Missing 2 (11) 0
Bulky disease, n (%)* .414
<5 cm 3 (17) 12 (19)
5 cm 3 (17) 19 (31)
Missing 12 (66) 31 (50)
Disease status before allo-HCT, n (%) .453
Primary induction failureeresistant 37 (50) 57 (45)
Relapse-resistant 37 (50) 71 (55)
Transplantation related
Interval from diagnosis to HCT, months, median (range) 15 (4-184) 29 (5-135) .001
Interval from auto-HCT to allo-HCT, months, median (range) 32 (7-69) 22 (8-77) .501
Number of previous chemotherapy lines, median (range) 3 (2-5) 4 (1-5) .024
Rituximab before HCT, n (%)* .013
Yes 11 (52) 52 (80)
No 10 (48) 13 (20)
Conditioning regimen, n (%)* NA
Cyclophosphamide/TBI 25 (53) 0
Busulfan/cyclophosphamide 13 (28) 0
TBI low-dose <500 cGY single/TBI <800 cGY fraction 0 5 (7)
Fludarabine/melphalan 0 23 (31)
Fludarabine/busulfan 0 10 (13)
TBI 200 cGY 0 11 (15)
Fludarabine þ TBI 200 cGY 0 15 (20)
Fludarabine þ cyclophosphamide 0 10 (13)
TBI 500 cGY single/TBI 800 cGY fraction 2 (4) 0
Busulfan >9 mg/kg 6 (13) 0
Busulfan þ melphalan 1 (2) 0
Cyclophosphamide, carmustine, þ etoposide/similar 0 1 (1)
Donorerecipient sex match, n (%) .351
Male-male 30 (41) 61 (48)
Male-female 5 (7) 18 (14)
Female-male 25 (34) 36 (28)
Female-female 4 (5) 11 (9)
Missing 10 (14) 2 (2)
Graft source, n (%) .719
Bone marrow 13 (18) 20 (16)
Peripheral blood 61 (82) 108 (84)
Type of donor, n (%)* <.001
HLA-identical sibling 47 (64) 37 (29)
Other relative 3 (4) 4 (3)
URD, well-matched 12 (16) 57 (45)
URD, partially matched 5 (7) 12 (9)
URD, mismatched 1 (1) 4 (3)
URD, HLA match unknown 6 (8) 14 (11)
Year of allo-HCT, n (%) .103
1998-2001 25 (34) 26 (20)
2002-2005 22 (30) 44 (34)
2006-2010 27 (36) 58 (45)
GVHD prophylaxis, n (%) .123
Ex vivo T cell depletion 5 (7) 1 (1)
Tacrolimus with and without others 32 (43) 67 (52)
Cyclosporine with and without others 29 (39) 51 (40)
CD34 selection 2 (3) 2 (2)
Other, not speciﬁed 6 (8) 7 (5)
Follow-up of survivors, months, median (range) 35 (3-124) 43 (4-96)
TBI indicates total body irradiation; URD, unrelated donor.
* Research-level patients only.
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Figure 1. Kaplan-Meier estimates of adjusted PFS after allo-HCT for mantle
cell lymphoma.
Table 2
Univariate Analysis
Outcome Event MA RIC/NST P
Value*
n Probability
(95% CI)
n Probability
(95% CI)
Time to ANC >0.5  109/L 58 117
28 days 90 (78-95) 92 (85-96) .579
100 days 90 (78-95) 94 (88-97) .343
Platelet recovery
20  109
39 91
28 days 72 (54-84) 80 (70-87) .337
100 days 82 (66-91) 87 (78-92) .510
Acute GVHD (grade II-IV) 50 98
100 days 36 (23-50) 37 (28-46) .930
Chronic GVHD 49 105
1 year 35 (22-48) 43 (33-52) .347
3 years 37 (24-51) 49 (39-58) .160
NRM 71 120
100 days 33 (23-45) 26 (18-34) .281
1 year 43 (31-54) 38 (29-48) .561
3 years 47 (35-59) 43 (34-53) .679
Relapse/progression 71 120
1 year 26 (17-38) 24 (16-32) .664
3 years 33 (22-45) 32 (23-41) .890
PFS 71 120
1 year 31 (20-42) 38 (29-48) .316
3 years 20 (11-32) 25 (17-34) .531
OS 74 128
1 year 33 (22-44) 46 (37-54) .066
3 years 25 (16-36) 30 (22-39) .455
ANC indicates absolute neutrophil count.
* Probabilities of neutrophil and platelet recovery, platelet recovery,
acute GVHD, chronic GVHD, treatment-related mortality and progression/
relapse were calculated using cumulative incidence estimates. PFS and OS
were calculated using Kaplan-Meier product limit estimates.
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RIC/NST group (29 months versus 15 months; P < .001).
No signiﬁcant difference at baseline was observed
between the 2 groups in terms of disease stage at diagnosis,
bone marrow or extranodal involvement, disease bulk,
central nervous system involvement, disease status at
transplantation (primary refractory disease versus refractory
at relapse) and graft type (bone marrow versus peripheral
blood). Signiﬁcantly more patients in the RIC/NST group had
a history of previous auto-HCT (33% versus 13%; P ¼ .004),
had received rituximab therapy before transplantation (41%
versus 15%; P ¼ .01), and had undergone unrelated donor
allo-HCT (68% versus 32%; P < .001). Patients in the RIC/NST
group were also more heavily pretreated (median lines of
previous chemotherapy, 4 versus 3; P ¼ .02). The most
frequently used MA conditioning regimens wereTable 3
Causes of Death
Cause of Death MA, n (%) RIC/NST, n (%)
Total number 56 93
Graft rejection 2 (4) 1 (1)
Infection 8 (14) 11 (12)
Pulmonary syndrome 0 2 (2)
Acute respiratory distress syndrome 0 1 (1)
GVHD 3 (5) 12 (13)
Primary disease 22 (39) 39 (42)
Organ failure 7 (13) 8 (9)
2nd malignancy 0 2 (2)
Hemorrhage 3 (5) 2 (2)
Accidental death 0 1 (1)
Vascular 0 1 (1)
Toxicity 2 (4) 3 (3)
Other cause, not speciﬁed* 9 (16) 10 (11)
* Six cases reported as “other HSCT related cause.”cyclophosphamide/total body irradiation and busulfan/
cyclophosphamide, whereas ﬂudarabine-based conditioning
was the most popular RIC-NST regimen. The majority of the
patients in both groups received calcineurin inhibitor-based
GVHD prophylaxis.
Outcomes
Outcomes after allo-HCT are summarized in Tables 2
and 3.
Engraftment and GVHD
The cumulative incidence of neutrophil engraftment at
day þ28 was 90% (95% conﬁdence interval [CI], 78%-95%) in
the MA group and 92% (95% CI, 85%-96%) in the RIC/NST
group (P¼ .58) (Table 2). The cumulative incidence of platelet
recovery at day þ28 was 72% (95% CI, 54%-84%) in the MA
group and 80% (95% CI, 70%-87%) in the RIC/NST group (P ¼
.34). The cumulative incidence of grade II-IV acute GVHD at
day þ100 was 36% (95% CI, 23%-50%) in the MA group and
37% (95% CI, 28%-46%) in the RIC/NST group (P ¼ .93)
(Table 2). The cumulative incidence of chronic GVHD at 1
year post-transplantation was 35% (95% CI, 22%-48%) in the
MA group and 43% (95% CI, 33%-52%) in the RIC/NST group
(P ¼ .35) (Table 2). In the MA group, chronic GVHD was
limited in 3 patients and extensive in 13 patients in the MA
group and limited in 12 patients and extensive in 36 patients
in the RIC/NST group. The extent of chronic GVHD (limited
versus extensive) was not known in 3 patients.
NRM
Day þ100 NRM rates were 33% (95% CI, 23%-45%) for the
MA group and 26% (95% CI, 18%-34%) for the RIC/NST group
(P ¼ .28) (Table 2). The bumulative incidence estimate of
NRM at 3 years was 47% (95% CI, 35%-59%) for the MA group
and 43% (95% CI, 34%-53%) for the RIC/NSTgroup (P¼ .68). On
multivariate analysis, receipt of a bone marrow allograft
compared with a peripheral blood graft (RR, 1.89; 95% CI,
1.10-3.24; P ¼ .02) and GVHD prophylaxis with ex vivo T cell
depletion or CD34þ selection compared with tacrolimus-
based GVHD prophylaxis (RR, 6.11; 95% CI, 2.60-14.36; P <
.001) were associated with an increased risk of NRM.
Conditioning regimen intensity was not associated
with NRM (MA versus RIC/NST; RR, 1.04; 95% CI, 0.66-1.63;
P ¼ .87).
Relapse/Progression
The 1- and 3-year probabilities of relapse/progression
were similar in the MA and the RIC/NST groups; at 3 years, it
Figure 2. Kaplan-Meier estimates of adjusted OS after allo-HCT for mantle cell
lymphoma.
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23%-41%) in the RIC/NST group (P ¼ .89) (Table 2). No
correlation was observed between the risk of relapse/
progression and development of grade II-IV acute GVHD (RR,
0.73; 95% CI, 0.35-1.51; P ¼ .39), grade III-IV acute GVHD (RR,
1.11; 95% CI, 0.52-2.36; P ¼ .78), or chronic GVHD (RR, 0.77;
95% CI, 0.35-1.58; P ¼ .45). None of the variables tested were
signiﬁcantly associated with a risk of relapse/progression on
multivariate analysis. Moreover, conditioning regimen
intensity was not associated with the risk of relapse/
progression onmultivariate analysis (MA versus RIC/NST; RR,
1.16; 95% CI, 0.68-1.99; P ¼ .59).
PFS
PFS estimates were not signiﬁcantly different in the MA
and RIC/NST groups at 1 year (31% [95% CI, 20%-42%] versus
38% [95% CI, 29%-48%]; P ¼ .32) or at 3 years (20% [95% CI,
11%-32%] versus 25% [95% CI, 17%-34%]; P ¼ .53) (Table 2). On
multivariate analysis, receipt of a bone marrow allograft
compared with a peripheral blood graft (RR, 1.72; 95% CI,
1.11-2.67; P ¼ .02) was associated with inferior PFS. Similarly
inferior PFS was associated with ex vivo T celledepleted or
CD34þ celleselected allo-HCT (RR, 4.89; 95% CI, 2.36-10.12; P
< .001). Conditioning regimen intensity was not associated
with PFS on multivariate analysis (MA versus RIC/NST, RR,
1.09; 95% CI, 0.77-1.56; P ¼ .60) (Figure 1).
OS
OS estimates were not signiﬁcantly different in the MA
and RIC/NST groups at 1 year (33% [95% CI, 22%-44%] versus
46% [95% CI, 37%-54%]; P ¼ .07) or at 3 years (25% [95% CI,
16%-36%] versus 30% [95% CI, 22%-39%]; P¼ .45) (Table 2). On
multivariate analysis, receipt of a bone marrow allograft
compared with a peripheral blood graft (RR, 1.84; 95% CI,
1.21-2.78; P ¼ .004) was associated with inferior OS. GVHD
prophylaxis with ex vivo T cell depletion/CD34þ selection
(RR, 3.42; 95% CI, 1.64-7.12; P ¼ .001) or with a cyclosporine-
based regimen (RR, 1.42; 95% CI, 1.00-2.02; P ¼ .04) also were
associated with inferior OS. Conditioning regimen intensity
was not associatedwith OS (MAversus RIC/NST, RR,1.22; 95%
CI, 0.86-1.72; P ¼ .25) (Figure 2).
Causes of Death
Disease relapse and/or progression accounted for 39%
(n¼ 22) of the mortality in the MA group and 42% (n¼ 39) in
the RIC/NST group. Causes of death are summarized in
Table 3.DISCUSSION
The aims of the present study were to deﬁne outcomes of
patients with chemotherapy-unresponsive MCL after allo-
HCT relative to the intensity of conditioning regimens and
other variables, including graft source and previous auto-
HCT. Our analysis of this large cohort of refractory MCL
patients undergoing allo-HCT in multiple centers has yielded
several important observations. First, despite refractory
disease at baseline, approximately 25% of the patients with
MCL were alive and in remission at 3 years after allo-HCT.
Second, in this uniquely chemotherapy-refractory group,
the intensity of the pretransplantation conditioning regimen
used apparently had no signiﬁcant affect on rates of NRM,
relapse/progression, PFS, and OS. Third, bone marrow as
a graft source and ex vivo T cell depletion seem to be asso-
ciated with inferior survival outcomes, likely owing due to
associated signiﬁcantly higher rates of NRM. Fourth, high
NRM and relapse rates after allo-HCT in this high-risk group
will continue to be the main barrier to wider application of
this modality.
Published data on the role of allo-HCT in patients with
chemotherapy-refractory MCL are limited (Table 4). The Fred
Hutchinson Cancer Center reported 2-year OS and PFS rates
of 65% and 60%, respectively, in a cohort of 33 patients with
MCL undergoing NST allo-HCT with ﬂudarabine and low-
dose total body irradiation [19]. Although that report
included 13 patients with refractory disease, these patients’
outcomes were not described separately. The M.D. Anderson
Cancer Center reported encouraging outcomes (6-year PFS
and OS of 46% and 53%, respectively) in 35 patients with
relapsed MCL after NST allo-HCT [27]. In that report, disease
remission at allo-HCT was not signiﬁcantly associated with
survival outcomes; however, the series included only 6
refractory patients. The British Society for Bone Marrow
Transplantation registry reported outcomes of RIC allo-HCT
for patients with MCL, including 12 refractory patients [28].
The 3-year OS and PFS rates for this very small subgroup of
refractory patients were only 38% and 0%, respectively. Along
similar lines, a recent French study reported 2-year OS of 31%
and 2-year PFS o 11% in a series of 15 refractory patients [29].
Our present study, the largest reported to date, indicates that
approximately 25% of patients with chemotherapy-
unresponsive MCL can attain a prolonged remission after
allo-HCT. It is important to interpret these results in the
context of the dismal long-term prognosis of patients with
refractory MCL treated with conventional chemotherapies,
as well as the fact that only 30%-40% of our patients had a KPS
90 before allo-HCT.
In patients with refractory lymphoid malignancies at the
time of allo-HCT, the relative importance of conditioning
regimen intensity is unknown. It is likely that, owing to their
inherent chemoresistance, patients with refractory NHL may
derive no net beneﬁt from higher-intensity conditioning
regimens. In the present study, the more-intense MA
conditioning regimens were not associated with a reduced
risk of relapse/progression or with improved OS and PFS.
However, our study included 2 different groups of patients
with signiﬁcant differences before undergoing allo-HCT. This
study is not a substitute for a randomized comparison of
high-intensity and low-intensity conditioning regimens. We
cannot discount inherent selection bias, that is, a tendency of
transplantation physicians to preferentially offer MA allo-
HCT to patients with higher-risk, primary refractory, or
blastoid MCL. Whether the MA group was enriched with
patients with progressive disease at the time of
Table 4
Studies Reporting Outcomes of Allo-HCT in at least 30 Patients with MCL
Study No. of
Patients
No. with
Refractory
Disease
Conditioning Relapse
Rate, % (Year)
NRM, %
(Year)
PFS, %
(Year)
OS, %
(Year)
PFS of RD
Patients, % (Year)
OS of RD
Patients, % (Year)
Maris et al. [19] 33 13 NST 9* (2) 24* (2) 60* (2) 65* (2) NR NR
Tam et al. [27] 35 6 NST NR 9* (1) 46* (6) 53* (6) NR NR
Cook et al. [28] 70 12 RIC 65* (5) 21* (5) 37* (5) 14* (5) 0 (3) 38 (3)
Le Gouill et al. [29] 70 15 RIC NR 32* (2) 50* (2) 53* (2) 11 (2) 31 (2)
CIBMTR (current) 202 202 RIC/NST and MA 33-32 (3) 43-47 (3) NA NA 20-25 (3) 25-30 (3)
NA indicates not applicable; NR, not reported.
* Includes chemosensitive patients.
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collected by the registry.
The time interval between diagnosis and allo-HCT was
shorter in the MA group compared with the RIC/NST group,
possibly indicating a more aggressive disease biology in the
former group. Of note, however, the patients in RIC/NST
group were more heavily pretreated and older, and a signif-
icantly higher proportion had previous rituximab exposure,
had undergone previous auto-HCT, or had received an
unrelated donor allograft. The latter 2 factors likely contrib-
uted to the longer time interval between diagnosis and
eventual allo-HCT in the RIC/NST group. With these limita-
tions in mind, our data suggest that in patients with MCL
who are refractory to conventional therapies, escalating the
intensity of conditioning regimens is unlikely to improve
patient outcomes.
It is important to point out that our report included both
registration- and research-level patients reported to the
CIBMTR. The primary objective of this study was to describe
transplantation outcomes in patients with chemorefractory
MCL relative to the intensity of conditioning regimens.
Noteworthy variables missing in registration-level patients
include disease stage at diagnosis, history of radiation
exposure, bulky disease status, B symptoms, serum lactate
dehydrogenase level, bone marrow involvement, and extra-
nodal involvement at any time point before allo-HCT.
Although some of these variables have prognostic value for
MCL, the signiﬁcance of their presence at any time point
before transplantation (as opposed to their presence at the
time of transplantation) in an exclusive cohort of patients
with chemotherapy-refractory MCL is not known. Because
key data regarding remission status at transplantation, type
of conditioning regimen, donor/graft source, patient age,
KPS, history of previous auto-HCT and all post-
transplantation outcomes of interest (eg, engraftment,
GVHD, NRM, OS, PFS) were available on both registration-
and research-level patients, we decided to include both
patient populations.
The 3-year relapse/progression rate of 30% and NRM rate
of 45% in our study cohort are high. In previous reports of
predominantly chemosensitive MCL undergoing RIC/NST
allo-HCT, the rates of disease relapse at 5 years have ranged
from 30% to 65% [27,28], whereas reported 2-year NRM are
approximately 20%-35% [19,29]. One-third of our RIC/NST
allo-NCT recipients had undergone previous auto-HCT,
a possible reason for the high NRM in our cohort. Our
multivariate analysis did not identify this factor as associated
with a higher NRM. Moreover, other investigators have not
consistently found that previous auto-HCT signiﬁcantly
inﬂuences NRM after allo-HCT [16,17]. Nonetheless, the
urgent need to mitigate NRM and relapse rates through the
development of novel conditioning regimens designed toprovide improved disease control while maintaining
acceptable NRM rates is clear. Along these lines, in a cohort
composed predominately of patients with refractory B cell
NHL, Gopal et al. [30] reported a 30-month 54% survival with
a NRM rate of 16% with radioimmunotherapy-based NST
ﬁndings, similar to those of Bethge et al. [31].
In the present study, on multivariate analysis, bone
marrow as graft source and ex vivo T cell depletion/CD34þ
cell selection were consistently associated with higher NRM
and inferior PFS and OS. Considering that these 2 variables
were not associated with an elevated risk of disease relapse/
progression, we speculate that the inferior OS and PFS in
these patients are likely related to higher rates of NRM. A
possible explanation for the higher NRM with bone marrow
allografts and ex vivo T cell depletion is delayed immune
reconstitution and the resulting increased susceptibility to
infectious complications in these patients. Nonetheless,
caution must be exercised when interpreting these results,
owing to the small number of patients in the subgroup that
underwent ex vivo T cell depletion/CD34þ cell selection. The
use of peripheral blood as a graft source has been reported to
improve PFS in patients with MCL undergoing allo-HCT [27].
In conclusion, our analysis of this large set of registry data
demonstrates that approximately 25% of patients with
refractory MCL can attain durable remission after allo-HCT,
and that the intensity of the conditioning regimen does not
inﬂuence outcomes. In the absence of a clinical trial,
consideration of a Tcellereplete, allogeneic peripheral blood
transplant is a viable option for otherwise healthy patients
with refractory MCL.
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